XZEN GOLD Recalled for Undeclared Erectile Dysfunction Drug Ingredients
Nova Products, Inc. is voluntarily recalling XZEN GOLD capsules because FDA testing found undeclared sildenafil and tadalafil.
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 5/5 (Critical).
Highest-severity recall. The hazard can cause serious injury or death. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The agency classification is FDA Class I, which mandates a severity score of 5 per the rubric.
Plain-English summary
Nova Products, Inc. of Aston, Pennsylvania, is voluntarily recalling XZEN GOLD, 750 mg, six capsules per bottle. The product is distributed by XZEN in Los Angeles, California, and was distributed nationwide to retailers and distributors.
The recall is being conducted because FDA laboratory analysis determined that the capsules contain undeclared amounts of sildenafil and tadalafil. These are active ingredients of FDA-approved drugs used to treat erectile dysfunction. The product was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).
Consumers who have purchased XZEN GOLD, specifically Lot# 130310GL, should stop using the product and contact the recalling firm or their healthcare provider for further instructions.
The recalled product
- Product
- XZEN GOLD,750 mg, six capsules per bottle, Distributed by: XZEN, City of Los Angeles, CA 90012
- Manufacturer
- Nova Products, Inc.
- Category
- Drug — Supplement
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot# 130310GL
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 8 recalled by Nova Products, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 8 products in this recall →Related recalls
Same manufacturer · Nova Products, Inc.
See all →- SevereXZONE GOLD recalled for undeclared erectile dysfunction drug ingredients
FDA (Drugs) · 2014-09-24
- SevereXZone 1200 Recalled for Undeclared Erectile Dysfunction Ingredients
FDA (Drugs) · 2014-09-24
- CriticalAfrican Black Ant supplement recalled for undeclared sildenafil
FDA (Drugs) · 2014-09-24
- CriticalNova Products Recalls Black Ant for Undeclared Sildenafil
FDA (Drugs) · 2014-09-24
- CriticalXZEN Platinum Recalled for Undeclared Erectile Dysfunction Drug Ingredients
FDA (Drugs) · 2014-09-24
Same hazard · undeclared ingredients
See all →- CriticalFDA Recalls Addall XR Shot Liquid Dietary Supplement
FDA (Food) · 2026-09-02
- SevereD'Dioses Mango Ice Pops Recalled for Undeclared Allergens
FDA (Food) · 2026-07-22
- ModerateSuper ProTHIN Plus Dietary Supplement Recalled for Undeclared Dyes
FDA (Food) · 2025-07-02
- LowGaiser's Recalls Ready-to-Eat Bologna Due to Undeclared Meat Ingredients
USDA FSIS · 2025-06-27
- HighFlour tortillas recalled due to undeclared wheat allergen
FDA (Food) · 2024-05-29
Similar recalls
- CriticalXZEN Platinum Recalled for Undeclared Sildenafil and Tadalafil
FDA (Drugs) · 2014-05-28
- SeverePrimeZEN Black 6000 Capsule Recalled for Undeclared Pharmaceutical Ingredients
FDA (Drugs) · 2023-03-08
- CriticalXZONE GOLD Dietary Supplement Recalled for Undeclared Sildenafil and Tadalafil
FDA (Drugs) · 2014-05-28
- SeverePremierZEN Gold 7000 Capsule Recalled for Undisclosed Drug Contamination
FDA (Drugs) · 2021-06-30
- CriticalShogun-X Capsules Recalled for Undeclared Prescription Drug Ingredients
FDA (Drugs) · 2021-07-28
- SevereNUX Male Enhancement Capsules Recalled for Undeclared Prescription Ingredients
FDA (Drugs) · 2023-05-10